Correlation Between Citius Oncology, and Verve Therapeutics
Can any of the company-specific risk be diversified away by investing in both Citius Oncology, and Verve Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Citius Oncology, and Verve Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Citius Oncology, and Verve Therapeutics, you can compare the effects of market volatilities on Citius Oncology, and Verve Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Citius Oncology, with a short position of Verve Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Citius Oncology, and Verve Therapeutics.
Diversification Opportunities for Citius Oncology, and Verve Therapeutics
0.3 | Correlation Coefficient |
Weak diversification
The 3 months correlation between Citius and Verve is 0.3. Overlapping area represents the amount of risk that can be diversified away by holding Citius Oncology, and Verve Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Verve Therapeutics and Citius Oncology, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Citius Oncology, are associated (or correlated) with Verve Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Verve Therapeutics has no effect on the direction of Citius Oncology, i.e., Citius Oncology, and Verve Therapeutics go up and down completely randomly.
Pair Corralation between Citius Oncology, and Verve Therapeutics
Given the investment horizon of 90 days Citius Oncology, is expected to generate 1.44 times more return on investment than Verve Therapeutics. However, Citius Oncology, is 1.44 times more volatile than Verve Therapeutics. It trades about 0.04 of its potential returns per unit of risk. Verve Therapeutics is currently generating about -0.04 per unit of risk. If you would invest 103.00 in Citius Oncology, on September 3, 2024 and sell it today you would earn a total of 1.00 from holding Citius Oncology, or generate 0.97% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Citius Oncology, vs. Verve Therapeutics
Performance |
| Timeline |
| Citius Oncology, |
| Verve Therapeutics |
Citius Oncology, and Verve Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Citius Oncology, and Verve Therapeutics
The main advantage of trading using opposite Citius Oncology, and Verve Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Citius Oncology, position performs unexpectedly, Verve Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Verve Therapeutics will offset losses from the drop in Verve Therapeutics' long position.| Citius Oncology, vs. Connect Biopharma Holdings | Citius Oncology, vs. Acumen Pharmaceuticals | Citius Oncology, vs. Nuvation Bio | Citius Oncology, vs. Eledon Pharmaceuticals |
| Verve Therapeutics vs. DiaMedica Therapeutics | Verve Therapeutics vs. Lyra Therapeutics | Verve Therapeutics vs. Centessa Pharmaceuticals PLC |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Complementary Tools
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |